We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




New Blood Test Improves Diagnosis of Alzheimer’s Disease

By LabMedica International staff writers
Posted on 17 Feb 2025
Print article
Image: The Lumipulse G plasma p-tau217 assay allows for better diagnosis of Alzheimer’s Disease (Photo courtesy of Fujirebio)
Image: The Lumipulse G plasma p-tau217 assay allows for better diagnosis of Alzheimer’s Disease (Photo courtesy of Fujirebio)

In Ireland, more than 60,000 people are living with dementia, with Alzheimer’s Disease (AD) accounting for approximately 70% of these cases. Of those living with AD in Ireland, up to half have not received a formal diagnosis, underscoring the need for better diagnostic methods that are both accurate and scalable. To facilitate precise diagnosis, biomarkers are typically measured in cerebrospinal fluid (CSF) obtained via a diagnostic lumbar puncture (LP), a procedure that is invasive and carries associated risks and challenges. Now, a new blood test could revolutionize patient care, offering the potential for improved AD diagnosis, earlier intervention, and more targeted treatment options.

A collaborative study involving researchers from Trinity College (Dublin, Ireland) is investigating the use of a new blood test, plasma p-tau217, to detect AD. The Lumipulse G plasma p-tau217 assay from Fujirebio (Tokyo, Japan) could potentially replace the current diagnostic method for over half of patients with early symptoms, thereby enabling more patients to be diagnosed accurately and efficiently. The study, published in Alzheimer’s & Dementia: Diagnosis, Assessment and Disease Monitoring, is one of the first in Europe to evaluate the real-world effectiveness of plasma p-tau217, one of the leading automated blood tests for AD, in patients with mild symptoms who are undergoing evaluation in a specialist memory service.

In this study, 148 patients provided both blood and cerebrospinal fluid (CSF) samples during their LP procedure, allowing researchers to directly compare the new blood tests to established CSF biomarkers. Importantly, this was done using fully automated technology (Lumipulse), which is already in use in clinical diagnostic laboratories. The adoption of a fully automated system ensures consistent reliability over time in the laboratory, as well as greater consistency between different laboratories. The study revealed that plasma p-tau217 measurements using the automated system were over 90% as accurate as those obtained from LP. Integrating this blood test into clinical pathways could potentially eliminate the need for more than half of the diagnostic LPs currently conducted. This would have significant implications for the diagnosis and management of early AD. Based on their findings, the research team believes that this new blood test could replace over half of the 150-200 diagnostic LP procedures currently performed annually.

"This study brings us one step closer to using diagnostic blood tests, such as plasma p-tau217, to assist in the clinical-biological diagnosis of early Alzheimer’s Disease,” said Dr. Adam Dyer, Specialist Registrar in Geriatric Medicine & Clinical Lecturer in Medical Gerontology, Trinity College Dublin. “Importantly, this research assessed plasma p-tau217 using fully-automated technology already available in clinical laboratories and used samples from a "real-world" clinical cohort."

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.